

What Is Claimed Is:

1. A method of killing a cancer cell, the method comprising contacting the cancer cell with an inhibitor of a gene selected from the group consisting of CDK8, STK33, PRKCM, PRKACA, ACVR1B, CDK5R1, CDC42BPB, MPP6, and CDC42BPA.
2. The method of claim 1, wherein the inhibitor is contacted to the cancer cell in a sterile composition comprising a pharmaceutically acceptable carrier.
3. The method of claim 1, wherein the inhibitor is an siRNA.
4. A sterile pharmaceutical composition comprising a nucleic acid capable of inhibiting a gene selected from the group consisting of CDK8, STK33, PRKCM, PRKACA, ACVR1B, CDK5R1, CDC42BPB, MPP6, and CDC42BPA in a pharmaceutically acceptable carrier.
5. An inhibitor of the expression of a gene selected from the group consisting of CDK8, STK33, PRKCM, PRKACA, ACVR1B, CDK5R1, CDC42BPB, MPP6, and CDC42BPA comprising an oligonucleotide having a nucleotide sequence selected from the group consisting of SEQ ID NOS: 1-6 and 11-78.